Beijing Chest Hospital

Futó vizsgálatok

• Toboroz

  A Study of DS-3939a in Participants With Solid Tumors

  NCT07739966· 1/2. fázis· Forrás

• Még nem toboroz

  Safety and Efficacy of Nebulized 3D-cultured Human Placental Mesenchymal Stem Cell-derived Extracellular Vesicles (hPMSC-EVs) for Idiopathic Pulmonary Fibrosis

  NCT07515066· 1. fázis· Forrás

• Toboroz

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· 3. fázis· Forrás

• Toboroz

  A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection

  NCT07367529· 1/2. fázis· Forrás

• Toboroz

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· 3. fázis· Forrás

• Toboroz

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· 3. fázis· Forrás

• Toboroz

  A 15-year Cohort Study on Risk Factors of Mortality in Patients With Intestinal Tuberculosis

  NCT07575061· Forrás

• Még nem toboroz

  A Prospective Multicenter Study of the Association Between TCM Syndromes and EGFR-TKI Efficacy in Lung Cancer Patients

  NCT07338396· Forrás

• Toboroz

  Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

  NCT07185997· 3. fázis· Forrás

• Toboroz

  A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical Surgery

  NCT07182682· 3. fázis· Forrás

• Toboroz

  Asymptomatic TB With Innovative Modified Short-course Regimens

  NCT06153069· 4. fázis· Forrás

• Toboroz

  A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

  NCT07209761· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors

  NCT07160335· 1. fázis· Forrás

• Toboroz

  A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets

  NCT07170800· 2. fázis· Forrás

• Toboroz

  A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

  NCT06855771· 2. fázis· Forrás

• Toboroz

  Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above

  NCT07152639· 3. fázis· Forrás

• Toboroz

  Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)

  NCT07079475· 1/2. fázis· Forrás

• Toboroz

  Short-term Antibiotic Therapy in Mycobacterium Avium Complex Pulmonary Disease

  NCT07213765· 4. fázis· Forrás

• Toboroz

  This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

  NCT06758401· 3. fázis· Forrás

• Toboroz

  A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC

  NCT06962865· 2. fázis· Forrás

• Toboroz

  A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

  NCT07010263· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

  NCT06623136· 2. fázis· Forrás

• Toboroz

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· 3. fázis· Forrás

• Toboroz

  Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

  NCT07087223· 1/2. fázis· Forrás

• Még nem toboroz

  Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.

  NCT06885840· 2. fázis· Forrás

• Toboroz

  A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

  NCT06914128· 1/2. fázis· Forrás

• Toboroz

  Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)

  NCT06809764· Forrás

• Toboroz

  Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

  NCT06712355· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer

  NCT07005336· 2. fázis· Forrás

• Toboroz

  Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

  NCT06712316· 2/3. fázis· Forrás

• Fut, nem toboroz

  A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)

  NCT06593522· 2. fázis· Forrás

• Fut, nem toboroz

  Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort

  NCT06649721· 3. fázis· Forrás

• Toboroz

  A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

  NCT06959615· 1/2. fázis· Forrás

• Fut, nem toboroz

  A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06711900· 3. fázis· Forrás

• Toboroz

  A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  NCT06452277· 3. fázis· Forrás

• Toboroz

  Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC

  NCT06467617· 2. fázis· Forrás

• Toboroz

  JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

  NCT06416410· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06448312· 3. fázis· Forrás

• Toboroz

  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· 3. fázis· Forrás

• Toboroz

  A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

  NCT06203210· 3. fázis· Forrás

• Toboroz

  A Prospective, Single-arm, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Tafolecimab and Sintilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Driver Gene-negative Non-small Cell Lung Cancer After Failure of First-line Immunotherapy.

  NCT06421298· 2. fázis· Forrás

• Toboroz

  D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

  NCT06300177· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer

  NCT06984588· 2/3. fázis· Forrás

• Fut, nem toboroz

  A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

  NCT06012435· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

  NCT06010329· 2. fázis· Forrás

• Toboroz

  A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

  NCT05920356· 3. fázis· Forrás

• Még nem toboroz

  A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

  NCT05990127· 3. fázis· Forrás

• Fut, nem toboroz

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

  NCT05899608· 3. fázis· Forrás

• Toboroz

  A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer

  NCT05913089· 2. fázis· Forrás

• Fut, nem toboroz

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák31 toboroz
• Tuberkulózis6 toboroz
• Hasnyálmirigyrák3 toboroz
• Vastagbélrák2 toboroz
• Elhízás1 toboroz
• Glioblasztóma1 toboroz
• Gyermekkori daganatok1 toboroz
• Idiopátiás tüdőfibrózis1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Leállították

  Evaluating the Preliminary Efficacy and Safety of JS207 in NSCLC After Progression Following Platinum-based Chemotherapy and Immunotherapy

  NCT06924606· 2. fázis· Forrás

• Lezárult

  A Study of Participants in China With Non-Small-Cell Lung Cancer That is Unable to be Treated With Surgery

  NCT05872763· Forrás

• Lezárult

  Real-world Study on Edoxaban Treatment for Patients With Non-valvular Atrial Fibrillation in China

  NCT04747496· Forrás

• Lezárult

  Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

  NCT04665856· 3. fázis· Forrás

• Lezárult

  Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

  NCT04447118· 3. fázis· Forrás

• Lezárult

  A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

  NCT04513925· 3. fázis· Forrás

• Lezárult

  A Real-world Study of Adjuvant Therapy in Early Stage NSCLC With EGFR Mutation-Positive in China

  NCT04830826· Forrás

• Lezárult

  A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151)

  NCT04194203· 3. fázis· Forrás

• Lezárult

  TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

  NCT04129502· 3. fázis· Forrás

• Lezárult

  A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

  NCT03909971· 2. fázis· Forrás

• Lezárult

  A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

  NCT03596866· 3. fázis· Forrás

• Lezárult

  Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

  NCT03358875· 3. fázis· Forrás

• Lezárult

  A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

  NCT02838420· 3. fázis· Forrás

• Lezárult

  A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

  NCT02716116· 1/2. fázis· Forrás

Vizsgálati helyszínek

• Beijing Chest Hospital20 vizsgálat
• Beijing Chest Hospital, Capital Medical Univerity1 vizsgálat
• Beijing chest hospital, Capital Medical University54 vizsgálat
• Beijing Chest Hospital, Capital Medical University /ID# 2322021 vizsgálat
• Beijing Chest Hospital,Capital Medical University (Site 0105)1 vizsgálat
• Beijing Chest Hospital,Capital Medical University (Site 3104)1 vizsgálat
• Beijing Chest Hospital,Capital Medical University (Site 4511)1 vizsgálat
• Beijing Chest Hospital,Capital Medical Unniversity1 vizsgálat
• Beijing Chest Hospital; Oncology Department1 vizsgálat
• Capital Medical University - Beijing Chest Hospital1 vizsgálat
• Beijing Chest Hospital1 vizsgálat

Betegségek

Betegségek, amelyekről az intézmény publikál vagy amelyekre vizsgálatot futtat.

• Tuberkulózis142 munka · 7 vizsgálat
• Tüdőrák105 munka · 71 vizsgálat